

Special Issue

Personalized Diagnosis, Treatment, and Prognosis of Gastrointestinal Oncology

Message from the Guest Editor

Cancers in digestive organs represent the most common malignant diseases, and they pose a major challenge to global public health. Although patients diagnosed with localized cancers can be treated with curable intent, tumor recurrence can occur at high rates. For patients with advanced unresectable or metastatic diseases, systemic treatment and/or palliative care remain the only options. Due to tumor heterogeneity among patients and between tumor sites in the same patient, the possibility of adopting effective personalized medicine for all patients remains a highly unmet need. As translational research has led to significant advances in screening and patient management, the individualized diagnosis, treatment, and prognosis of gastrointestinal tumors have become important clinical and research focuses. This Special Issue of *Journal of Personalized Medicine* focuses on the screening, early detection, diagnosis, prevention, and clinical investigation of gastrointestinal cancer, including but not limited to multi-modality therapy, markers, imaging, and tumor biology.

Guest Editor

Dr. Nelson Yee

Penn State Cancer Institute, Penn State Health Milton S. Hershey Medical Center, 500 University Drive, Hershey, PA 17033-0850, USA

Deadline for manuscript submissions

closed (15 September 2023)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/135305

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).